An Update from Our Firm about COVID-19

Abraham, Watkins, Nichols, Sorrels, Agosto, Aziz & Stogner remains fully operational and committed to serving our clients and colleagues throughout the Coronavirus (COVID-19) crisis. As we follow the CDC guidelines and practice social distancing, we remain available for phone consultations and remote meetings with both current and prospective clients and colleagues. Please contact our office by email or by calling 713-222-7211 with any questions. We look forward to hearing from you.

FDA Advisory Committee Favors Approval of New Prescription Weight-Loss Medication

Photo of Muhammad Aziz

A Food and Drug Administration (FDA) advisory committee recently recommended approval of the weight-loss drug Qnexa. Qnexa is a combination of two existing drugs. It is composed of the appetite suppressant phentermine, which was part of the fen-phen combination, and the anti-seizure medication topiramate, more commonly known by its brand name Topomax. Pre-approval studies show that using Qnexa led to an average weight loss of ten percent of body weight after one year. In addition, positive effects on blood pressure, blood sugar, and some blood lipids were also noted. However, the studies also showed that Qnexa increased heart rate which is a danger signal that the drug might actually be a dangerous drug if it increases the risk of heart attack.

The committee voted 20 to 2 that the benefits of Qnexa more than offset the potential risks of heart problems and birth defects. This overwhelmingly positive vote came as a surprise to many due to the fact that the same advisory committee voted 10 to 6 against Qnexa in 2010. The FDA is expected to issue a decision regarding approval or non-approval of Qnexa by April 17th. If Qnexa secures FDA approval, Qnexa would be the first new prescription weight-loss medication in over a decade.

If you or someone you know has been harmed while taking a weight loss drug, contact the attorneys at Abraham, Watkins, Nichols, Sorrels, Agosto & Friend by calling 713-396-3964 or 1-800-594-4884.

No Comments

Leave a comment
Comment Information
  • $50+ Million Personal Injury Fire and Explosion

    The firm successfully represented nearly 100 victims who suffered personal injuries and damages to property from a large fire and explosion resulting in a settlement of more than $50 million. The firm served as lead lawyers on the steering committee in this litigation.

  • $80 Million Personal Injury Large Plant Explosion

    The firm successfully represented 270 plaintiffs, taking a lead role in the plaintiffs’ steering committee, who suffered injuries in a large plant explosion resulting in a settlement of nearly $80 million.

  • $50+ Million Personal Injury Plant Fire and Explosion

    The firm successfully represented 45 personal injury victims in a plant fire and explosion, serving on the plaintiffs steering committee, concluding with a settlement of more than $50 million.

  • $22+ Million Personal Injury Work Site Accident

    The firm prevailed in a personal injury trial for a worksite injury client with the jury returning a verdict and resulting in a judgment of over $22 million for the firm’s client.

  • $12 Million Auto Accident 18-Wheeler Collision

    The firm successfully achieved a $12 million settlement for the family of a man who died in an 18 wheeler collision.

  • $30 Million Personal Injury Burn Victims

    The firm prevailed on behalf of three burn victims with settlements totaling nearly $30 million.

Our Record Of Success

When you are hurt and you choose a law firm to represent you in court or at the negotiation table, you need to carefully consider the firm's record.

Read More Success Stories

Let Us Help You Request a Free Consultation Today

Get Help Now

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

Back to top